Log in

NASDAQ:ARNAArena Pharmaceuticals Stock Price, Forecast & News

$45.09
+1.10 (+2.50 %)
(As of 04/6/2020 02:33 AM ET)
Add
Compare
Today's Range
$43.45
Now: $45.09
$45.44
50-Day Range
$34.83
MA: $45.51
$54.15
52-Week Range
$32.95
Now: $45.09
$64.48
Volume665,657 shs
Average Volume821,573 shs
Market Capitalization$2.27 billion
P/E Ratio5.90
Dividend YieldN/A
Beta1.34
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More
Arena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$8.08 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million

Miscellaneous

Employees194
Market Cap$2.27 billion
Next Earnings Date5/13/2020 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.


Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARNA stock has increased by 11.6% and is now trading at $45.09. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arena Pharmaceuticals.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Arena Pharmaceuticals.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Wednesday, February, 26th. The biopharmaceutical company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.55) by $0.21. The biopharmaceutical company earned $3 million during the quarter, compared to the consensus estimate of $1.06 million. Arena Pharmaceuticals had a net margin of 49.30% and a return on equity of 34.11%. During the same quarter in the previous year, the business posted $1.35 EPS. View Arena Pharmaceuticals' earnings history.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

6 analysts have issued 1-year price targets for Arena Pharmaceuticals' shares. Their forecasts range from $56.00 to $95.00. On average, they expect Arena Pharmaceuticals' share price to reach $69.60 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts' price targets for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Arena Pharmaceuticals is focused on developing its two pipeline candidates — etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations and out-licensing of Belviq to focus on the pipeline is prudent in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in the market, due to competition." (12/30/2019)
  • 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)

Has Arena Pharmaceuticals been receiving favorable news coverage?

News stories about ARNA stock have trended very negative on Monday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutArena Pharmaceuticals.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Canopy Growth (CGC), Cytokinetics (CYTK), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), AT&T (T), ZIOPHARM Oncology (ZIOP), NVIDIA (NVDA), Amarin (AMRN) and Bank of America (BAC).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $45.09.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.27 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe. View additional information about Arena Pharmaceuticals.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is http://www.arenapharm.com/.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

This page was last updated on 4/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel